JLK Inc (322510) - Cash Flow Conversion Efficiency
Based on the latest financial reports, JLK Inc (322510) has a cash flow conversion efficiency ratio of -0.056x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-1.94 Billion ≈ $-1.32 Million USD) by net assets (₩34.70 Billion ≈ $23.52 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see JLK Inc (322510) market capitalisation for the company's overall valuation and market capitalisation.
JLK Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how JLK Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
JLK Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of JLK Inc ranked by their cash flow conversion efficiency. Explore 322510 cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kyongbo Pharmaceutical Co Ltd
KO:214390
|
-0.004x |
|
La Kaffa International Co Ltd
TWO:2732
|
0.098x |
|
South Basic Chemicals JSC
VN:CSV
|
0.042x |
|
Prozone Realty Limited
NSE:PROZONER
|
0.044x |
|
Kyungdong City Gas Co Ltd
KO:267290
|
0.112x |
|
Intech Biopharm Ltd
TWO:6461
|
-0.085x |
|
Toma as
PR:TOMA
|
N/A |
|
FitLife Brands, Inc. Common Stock
NASDAQ:FTLF
|
0.077x |
Annual Cash Flow Conversion Efficiency for JLK Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of JLK Inc from 2017 to 2025. View JLK Inc (322510) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩41.36 Billion ≈ $28.03 Million |
₩-12.34 Billion ≈ $-8.36 Million |
-0.298x | -34.56% |
| 2024-12-31 | ₩49.32 Billion ≈ $33.42 Million |
₩-10.94 Billion ≈ $-7.41 Million |
-0.222x | +59.24% |
| 2023-12-31 | ₩11.72 Billion ≈ $7.95 Million |
₩-6.38 Billion ≈ $-4.32 Million |
-0.544x | -14.45% |
| 2022-12-31 | ₩16.62 Billion ≈ $11.26 Million |
₩-7.90 Billion ≈ $-5.35 Million |
-0.475x | -87.81% |
| 2021-12-31 | ₩24.08 Billion ≈ $16.32 Million |
₩-6.10 Billion ≈ $-4.13 Million |
-0.253x | -88.59% |
| 2020-12-31 | ₩30.67 Billion ≈ $20.78 Million |
₩-4.12 Billion ≈ $-2.79 Million |
-0.134x | +24.14% |
| 2019-12-31 | ₩36.30 Billion ≈ $24.60 Million |
₩-6.42 Billion ≈ $-4.35 Million |
-0.177x | +71.77% |
| 2018-12-31 | ₩6.10 Billion ≈ $4.13 Million |
₩-3.82 Billion ≈ $-2.59 Million |
-0.627x | -268.97% |
| 2017-12-31 | ₩-8.64 Billion ≈ $-5.86 Million |
₩-3.21 Billion ≈ $-2.17 Million |
0.371x | -- |
About JLK Inc
JLK, Inc. provides diagnosis support to the patients with its AI-driven medical platform in South Korea. The company offers AI medical and AI security solutions. Its AI platform provides on-site/real-time service that is connected to various systems built in the hospital and enables the professional needs of physicians to diagnose diseases. The company provides medical management, medical treatme… Read more